Press

Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression

Apr 29 • 5 min read

LONDON, April 29, 2024 (GLOBE NEWSWIRE) — Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a…

Lophos Pharmaceuticals Corp. Expands Peyote Cultivation with the Successful Planting of 3,000 Seeds

Apr 29 • 3 min read

VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”) proudly announces a milestone accomplishment from its subsidiary, Lophos Pharmaceuticals Corp. Specializing in the cultivation, research, and commercialization of peyote, the company has completed the propagation of an additional three thousand (3,000) seeds, marking a significant expansion…

Cybin to Participate at the 27th Annual Milken Institute Global Conference

Apr 29 • 3 min read

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference on a panel entitled “Collaborating for Improved Mental…

MindMed to Present at Upcoming May Medical Conferences

Apr 29 • 2 min read

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of…

MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry

Apr 24 • 3 min read

VANCOUVER – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6), (the ‘Company’ or ‘MindBio’), a clinical stage biopharma company uniquely pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines is pleased to announce publication of its scientist’s sleep research in the prestigious Nature portfolio journal Translational Psychiatry. MindBio’s unique investment thesis in the sector, is that small,…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435